NEW YORK (360Dx) – Immunodiagnostics firm Singulex announced today that it has formed a strategic collaboration with Qiagen to develop companion diagnostics.

Under the terms of the deal, Qiagen will combine Singulex's single-molecule counting (SMC) technology with its own molecular testing services to develop companion diagnostics. Qiagen will also have access to Singulex's CLIA lab. The companies aim to collaborate in a range of disease applications, Singulex said.

Additional terms were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.